

PODCAST

Current highlights in lung cancer in 2021

K. H. J. Lim^{1,2*} & B. J. Solomon³

¹Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; ²Department of Immunology and Inflammation, Imperial College London, London, UK; ³Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Available online XXX

[Click here to listen to the Podcast](#)

There continue to be significant advances made in the field of lung cancer improving survival outcomes for patients. In this podcast, Dr Jonathan Lim (a member of the European Society for Medical Oncology Young Oncologists Committee) discusses with Prof. Ben Solomon (professor of thoracic medical oncology) his highlights on lung cancer so far in 2021.

Prof. Solomon summarises key practice-changing studies so far this year, in particular, with updates from IMpower010 (adjuvant), CheckMate 816 (neoadjuvant) and CheckMate 9LA (metastatic) phase III clinical trials in non-small-cell lung cancer (NSCLC). They also discuss where we are at with targeting *KRAS* and some of the more novel agents to watch out for on the horizon. Finally, Prof. Solomon shares his opinion on what remains the key challenges in managing NSCLC in our daily practice and the future outlook in the field.

FUNDING

None declared.

DISCLOSURE

KHJL has received speaker honorarium from Janssen, outside the submitted work and is currently funded by the Wellcome Imperial 4i Clinical Research Fellowship. BJS has received advisory board/honoraria from Roche/Genentech, AstraZeneca, Pfizer, Novartis, Bristol-Myers-Squibb, Merck, Amgen, and Loxo oncology, outside the submitted work.

FURTHER READING

- IMpower010—https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8500
- CheckMate 816—<https://www.abstractsonline.com/pp8/#!/9325/presentation/5134>
- CheckMate 9LA—primary paper: [https://doi.org/10.1016/S1470-2045\(20\)30641-0](https://doi.org/10.1016/S1470-2045(20)30641-0); update: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9000

*Correspondence to: Dr Kok Haw Jonathan Lim, Department of Medical Oncology, The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 2TY, UK. Tel: +44 (0) 161 446 3000
E-mail: jonathan.lim@doctors.org.uk (K. H. J. Lim).

2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).